biostudies-literatureUnknown31(9)Tranby EP<h4>Background</h4>This study compared prevalence, incidence, mortality rates, treatment costs, and risk factors for oral and oropharyngeal cancer (OC/OPC) between two large United States adult cohorts in 2012-2019.<h4>Methods</h4>Medicaid and commercial claims data came from the IBM Watson Health MarketScan Database. Logistic regression analyses estimated incidence and risk factors for OC/OPC. Mortality was calculated by merging deceased individuals' files with those of the existing cancer cohort. Summing costs of outpatient and inpatient services determined costs.<h4>Results</h4>Prevalence of OC/OPC in Medicaid enrollees decreased each year (129.8 cases per 100,000 enrollees in 2012 to 88.5 in 2019); commercial enrollees showed a lower, more stable prevalence (64.7 per 100,000 in 2012 anCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology1849-1857https://www.ebi.ac.uk/biostudies/studies/S-EPMC9437560biostudies-literatureOral Cancer Prevalence, Mortality, and Costs in Medicaid and Commercial Insurance Claims Data.PMC9437560Frantsve-Hawley JTranby EPBackley MTomar SLFager GLHeaton LJKelly ALfalseOral Cancer Prevalence, Mortality, and Costs in Medicaid and Commercial Insurance Claims Data.<h4>Background</h4>This study compared prevalence, incidence, mortality rates, treatment costs, and risk factors for oral and oropharyngeal cancer (OC/OPC) between two large United States adult cohorts in 2012-2019.<h4>Methods</h4>Medicaid and commercial claims data came from the IBM Watson Health MarketScan Database. Logistic regression analyses estimated incidence and risk factors for OC/OPC. Mortality was calculated by merging deceased individuals' files with those of the existing cancer cohort. Summing costs of outpatient and inpatient services determined costs.<h4>Results</h4>Prevalence of OC/OPC in Medicaid enrollees decreased each year (129.8 cases per 100,000 enrollees in 2012 to 88.5 in 2019); commercial enrollees showed a lower, more stable prevalence (64.7 per 100,000 in 2012 an2022-01-01T00:00:00Z2022 Sep2025-04-04T21:04:17.188Z2025-04-04T21:04:17.188ZS-EPMC94375603573229110.1158/1055-9965.EPI-22-0114